2017
Submission from health consumers councils across Australia into the Number of women in Australia who have had transvaginal mesh implants and related matters
This submission was prepared by Dr Martin Whitely, Manager Policy and Research Health Consumers’ Council (WA) with substantial assistance from Carolyn Chisholm from the Australian Pelvic Mesh Support Group, Danny Vadasz of Health Issues Centre (Victoria) and Melissa Fox, CEO of Health Consumers Queensland. The survey cited in this paper was conducted by the Health Issues Centre (Victoria).
Submission to the Therapeutic Goods Administration consultation on the use of comparable overseas regulators for the regulation of medical devices
Prepared by Dr Martin Whitely Manager of Policy and Research
Submission on Therapeutic Goods Amendment Bill 2016
Prepared by Dr Martin Whitely Manager of Policy and Research
Understanding advocacy practice in mental health a multidimensional scalogram analysis of case records
Study conducted in partnership with Murdoch University, School of Health Professions, Murdoch and Health Consumers’ Council, East Perth, Australia. Paper written in 2015 and 2016 published in 2017.
Written by Paul Morrison, Norman Stomski, Martin Whitely and Pip Brennan
Advocacy processes in mental health a qualitative study
Study conducted in partnership with Murdoch University, School of Health Professions, Murdoch and Health Consumers’ Council, East Perth, Australia. Paper written in 2015 and 2016 published in 2017.
Written by Norman Stomski, Paul Morrison, Martin Whitely, and Pip Brennan
2014
Regulating Pharmaceuticals in Australia – Reforms needed to deliver Transparency and Safety
Prepared by Dr Martin Whitely Manager of Policy and Research
Establishing National Priorities for Clinical Practice Guidelines in Australia
Dr Ann Jones and Dr Martin Whitely made a submission on behalf of the HCC to the Australian Commission on Safety and Quality in Health Care regarding Australian disease treatment guideline development. The submission recommended that before any topics are prioritised for guideline development, there needs to be standardised processes to ensure the integrity of guidelines. The submission stressed the need for transparency, and independent robust evidence in guideline development processes.
Australian Commission on Safety and Quality in Health Care Submission
Licensing and Subsidising Pharmaceuticals in Australia – Reforms needed to deliver Transparency, Safety and Value for Money
Prepared by Dr Martin Whitely Manager of Policy and Research
Transcript of Senate Select Committee on Health Hearing – Licensing and Subsidising Pharmaceuticals in Australia
Dr Martin Whitely and Dr Ann Jones gave evidence at a Senate Select Committee on Health on 10 October 2014. Their appearance before the committee was to provide further information on the HCC submission to the Committee on the need for reforms to the way pharmaceuticals are regulated. Martin was also able to expand on concerns that the PBS and TGA often act in the best interest of pharmaceutical companies at the expense of health consumers.
For a full transcript of the hearing click on the link.